Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmacists Have Responsibility to Be "Drug Pros": Seminar
November 8, 2004
- AnGes MG Expecting 1st Product Launch in 2006
November 8, 2004
- Alan Bootes to Step Down as President of Pfizer Japan
November 8, 2004
- BULLETIN
November 8, 2004
- WORLD NEWS IN BRIEF
November 8, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 8, 2004
- REGULATORY NEWS IN BRIEF
November 8, 2004
- DIAGNOSTIC NEWS IN BRIEF
November 8, 2004
- 17 Types of Advanced Medical Technology Approved
November 8, 2004
- OTC NEWS IN BRIEF
November 8, 2004
- Urgent Listing for Valixa Tab Approved
November 8, 2004
- Press Seminar
November 8, 2004
- Semi-annual Business Results
November 8, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 8, 2004
- Business Forecast
November 8, 2004
- Postoperative Adjuvant Therapy Recommended as Grade A Standard for Lung Cancer: JLCS
November 8, 2004
- BUSINESS NEWS IN BRIEF
November 8, 2004
- GL on Clinical Evaluation of Anti-Malignant Tumor Agents Revised
November 8, 2004
- Degussa Japan Opens New Pharmapolymers Technical Center
November 8, 2004
- Length of Clinical Trials Averages 555 Days: JPMA
November 8, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…